CYTH - Cyclo Therapeutics stock surges on promising early-stage Trappsol Cyclo data

Cyclo Therapeutics (CYTH) announces positive topline data from its Phase 1/2 clinical trial, which showed promising safety and efficacy results for Trappsol Cyclo in the treatment of Niemann-Pick Disease type C1, a rare genetic disease causing cholesterol accumulation in cells, leading to dysfunction of liver, lung, spleen and brain and premature death.Shares up nearly 28% premarket.100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale.The multi-center, randomized, double-blind, parallel group trial without a placebo arm randomized 12 patients ranging in age from 2 to 39 years across clinical sites in the UK, Israel and Sweden.Trial data suggest that Trappsol Cyclo overcomes the NPC1 defect by removing trapped cholesterol from cells both systemically and in the central nervous system ((CNS)).

For further details see:

Cyclo Therapeutics stock surges on promising early-stage Trappsol Cyclo data